Search Videos and More
Video
Impact of Angiotensin Blockade on Response to PD1/L1 Inhibitors for Patients with Metastatic Urothelial Carcinoma (mUC)
Bladder cancer research presented by Dana-Farber's Guru Sonpavde, MD at ASCO #GU21: Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC) Abstract 453
Video
Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma
Kidney cancer research: Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma, presented by Vincent Wenxin Xu, MD at ASCO #GU21 abstract 342
Video
Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21
Video
The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC)
Kidney Cancer Research: Andrew Schmidt, MBBS presents a study that identifies a very favorable risk group in advanced kidney cancer patients treated with first-line therapy. ASCO #GU21 abstract 339.
Video
Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)
Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472
Video
Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study
Kidney Cancer Research: Toni Choueiri, MD details results from the phase 3 CLEAR study that showed significant benefits from the combination of lenvatinib, an oral kinase inhibitor, and pembrolizumab, a checkpoint inhibitor in advanced kidney cancer.
News
New Immunotherapy Target Discovered for Malignant Brain Tumors
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system.
News
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.
News
Targeted Therapy for Children with Leukemia Can Provide Substantial Benefit, Study Finds
Testing tumor tissue for genetic alterations that can be targeted by drugs, a mainstay of treatment in a variety of cancers, can benefit many children with leukemia, investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report in a new study. In some cases, such therapy can be lifesaving.
News
An Advanced Approach for Treating Localized Prostate Cancer
For many men diagnosed with early-stage, localized prostate cancer, external-beam radiation therapy offers the best chance of a cure.
News
First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors’ later years.
News
Dana-Farber Research Supports FDA Approval for Immunotherapy Combination in Advanced Kidney Cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.